Neuronetics Inc is a medical technology company focused on developing non-invasive solutions for mental health disorders
Primarily, the company specializes in the innovation and commercialization of neuromodulation therapies, particularly transcranial magnetic stimulation (TMS). This advanced treatment aims to address conditions such as depression and anxiety by using magnetic fields to stimulate nerve cells in the brain, promoting improved mood and cognitive function in patients. Neuronetics is dedicated to expanding access to evidence-based treatments, enhancing the quality of life for individuals struggling with mental health issues.
Neuronetics to acquire Greenbrook TMS (OTC: GBNHF) in an all-stock deal, doubling revenue to $145M. The combined company expects mid-teens growth in 2025 and 2026, with $15M in cost savings and positive EBITDA by 2025. Neuronetics to hold 57% ownership.
As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
